Breast Cancer and Immune Cell Interaction
Author Information
Author(s): Savas Burhan, Kerr Pauline E, Pross Hugh F
Primary Institution: Akdeniz University, Antalya, Turkiye
Hypothesis
The study investigates the susceptibility of multidrug resistant breast carcinoma cells to lymphokine-activated killer (LAK) cells and the role of adhesion molecules in this process.
Conclusion
The study found that multidrug resistant breast carcinoma cell lines have increased susceptibility to LAK cells, suggesting that IL-2 treatment could enhance the effectiveness of current cancer therapies.
Supporting Evidence
- MDR1 transfectant P-gp+ breast carcinoma lines had increased LAK susceptibility compared to their parent line.
- LAK cell-mediated lysis was significantly higher in MDR variants than in the drug-sensitive parent line.
- No significant differences in adhesion molecule expression were found between drug-sensitive and MDR breast carcinoma paired cell lines.
Takeaway
This study shows that some breast cancer cells that are resistant to drugs can still be attacked by special immune cells, which could help in treating the cancer.
Methodology
The study involved transfecting a breast cancer cell line with MDR1 genes and measuring LAK cell activity through chromium release assays and conjugate formation assays.
Potential Biases
Potential bias may arise from the use of a single cell line model and the specific conditions under which experiments were conducted.
Limitations
The study does not address the long-term effects of LAK cell therapy or the potential for further resistance development in cancer cells.
Participant Demographics
The study used peripheral blood lymphocytes from normal volunteers for LAK cell generation.
Statistical Information
P-Value
0.04
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website